グルカゴン受容体の欠乏は早期発症の肝硬変を引き起こす

Tessa M Cacciottolo¹, Katherine Lawler¹, Kevin M Méndez-Acevedo¹

¹University of Cambridge Metabolic Research Laboratories and National Institute for Health Research Cambridge Biomedical Research Centre, Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, U.K.

Diabetes

|August 25, 2025

まとめ

グルカゴン受容体 (GCGR) 遺伝子の変異は,血縁家族における肝硬変と肝硬変に関連していた. これらの発見は,GCGR調節を含む潜在的な治療戦略を示唆しています.

科学分野:

遺伝学
代謝障害
ヘパトロジー

背景:

肝硬変と肝硬変は,正常な体重の個体でも発生する.
血のつながった家族には遺伝学の研究のユニークな機会があります

研究の目的:

血縁の家族で肝硬変と肝硬変の遺伝的原因を特定する
グルカゴン受容体 (GCGR) の活性と脂質代謝に対する特定された遺伝子変異の機能的影響を理解する.

主な方法:

遺伝子変異を特定するために全エクソーム配列が採用されました.
フェノタイプによる変異の共分離を確認するために分離分析を行った.
GCGR変異の機能的影響を評価するために,細胞アッセイが使用されました.

主要な成果:

グルカゴン受容体 (GCGR) 遺伝子の2つの希少な同位体変異が特定されました.
これらのGCGR変異は,肝硬変と肝硬変に同期した.
インビトロ研究では,GCGR変異が機能の喪失と細胞内の脂質蓄積の増加につながることが示されました.

結論:

グルカゴン受容体 (GCGR) 遺伝子の機能喪失による変異は,肝硬変と肝硬変を引き起こす可能性があります.
GCGRアンタゴニストは,脂肪肝を発症する危険性がある.
GCGRアゴニストは,代謝性肝疾患の治療上の利点を提供することができる.

さらに関連する動画

04:14

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

12.1K

08:18

A Model of Chronic Nutrient Infusion in the Rat

Published on: August 14, 2013

12.8K

関連する概念動画

01:24

Glucagon-like Receptor Agonists

416

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

416

01:15

Hypoglycemia and Glucagon

334

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

334

01:27

Glucose Transporters

24.1K

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:

24.1K

01:28

Insulin: The Receptor and Signaling Pathways

1.5K

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...

1.5K

01:20

Inborn Errors of Metabolism

241

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...

241

01:16

Hormones Regulating Blood Glucose

4.0K

Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...